The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.
*Division of Surgical Oncology
∥Pediatric Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL
†Veneto Institute of Oncology, Pediatric Surgical Oncology Unit, Veneto
‡University Hospital of Padua, Pediatric Surgery Unit, Padua, Italy
The authors declare no conflict of interest.
Reprints: Mecker G. Möller, MD, FACS, 1120 Nw 14th Street, CRB 4th, Miami, FL 33131 (e-mail: email@example.com).
Received December 21, 2017
Accepted May 1, 2018